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ABSTRACT
Polygonum minus is a plant rich in flavonoids and antioxidants beneficial for reducing oxidative stress and lipid 
peroxidation in neuronal membranes. This randomized, double-blind, placebo-controlled study evaluated the potential 
benefits of P. minus extract (LineMinusTM) towards improving cognitive function, mood status and quality of life. Thirty 
five middle-aged women (35-55 years old) were randomized into intervention (n=17) and control group (n=18). Two 
capsules of P. minus (250 mg) or placebo (100 mg maltodextrin) each were taken once daily for six weeks. Cognitive 
tests, mood and anthropometric measurements were measured at baseline, week 3 and week 6, whilst biomarkers were 
measured at baseline and week 6. Parameters related to mood and quality of life including energy/fatigue, social 
functioning and general health significantly improved from baseline to week 6 in the intervention group (p<0.05). Mean 
score for cognitive tests (i.e. digit span, comprehensive trail making test (CTMT) and three domains of CNS vital sign 
(CNSVS)] improved significantly in both intervention and control groups (p<0.05). There was a significant decrease of 
mean uric acid, estimated glomerular filtration rate (eGFR), total cholesterol and glycated hemoglobin (HbA1C) in the 
intervention group from baseline to week 6. P. minus supplementation has the potential to improve mood and quality of 
life and no adverse effects were reported by the participants after 6 weeks supplementation.
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ABSTRAK
Polygonum minus adalah tumbuhan yang kaya dengan flavonoid dan antioksidan serta bermanfaat untuk mengurangkan 
tekanan oksidatif dan peroksidasi lipid pada membran neuron. Kajian ini berbentuk rawak, dwi-buta dan  plasebo 
terkawal untuk menilai potensi faedah ekstrak P. minus (LineMinusTM) dalam meningkatkan fungsi kognitif, status mood 
dan kualiti hidup. Tiga puluh lima wanita pertengahan umur (berumur 35-55 tahun) dibahagikan secara rawak ke 
dalam kumpulan intervensi (n=17) dan kumpulan kawalan (n=18). Dua kapsul P. minus (250 mg) atau plasebo (100 mg 
maltodekstrin) telah diambil setiap sehari selama enam minggu. Ujian kognitif, mood dan beberapa ukuran antropometri 
telah diukur pada peringkat dasar, minggu 3 dan minggu 6, manakala penanda biologi diukur pada peringkat dasar 
dan minggu 6. Parameter yang berkaitan dengan mood dan kualiti hidup termasuk tenaga/keletihan, fungsi sosial dan 
kesihatan meningkat secara signifikan pada peringkat dasar hingga minggu 6 untuk kumpulan intervensi (p<0.05). 
Min skor untuk ujian kognitif seperti Digit Span, Comprehensive Trail Making Test (CTMT) dan tiga domain CNS Vital 
Sign (CNSVS)] meningkat secara signifikan dalam kedua-dua kumpulan intervensi dan kawalan (p<0.05). Terdapat 
penurunan yang signifikan dalam min asid urik, anggaran kadar penapisan glomerular (EGFR), jumlah kolesterol dan 
hemoglobin glycated (HbA1C) dalam kumpulan intervensi pada peringkat dasar dan minggu 6. Pemberian P. minus 
mempunyai potensi untuk  memperbaik mood dan kualiti hidup serta tiada kesan buruk dilaporkan oleh peserta selepas 
pengambilan selama 6 minggu.
Kata kunci: Fitokimia; flavonoid; kualiti hidup; mood; Polygonum minus; suplemen
INTRODUCTION
Globally, there is an increase in the number of individuals 
with mental disorders related to neurological, behavioural 
and substances usage. The number has been predicted to 
increase up to 15% in the year 2020 (WHO 2004). There 
has been growing interest in the use of complementary 
and alternative medicines as a natural method for treating 
or preventing numerous mental disorders and improving 
cognitive function and mood. Several traditional herbs 
including passion flower, valerian root and kava have 
been utilized for centuries as remedies to assist in mind 
calmness and mood enhancement (Lakhan & Viera 2010). 
Furthermore, numerous studies have attempted to identify 
the efficacy and safety of utilizing alternative medicines 
in treating psychological problems specifically mental 
health such as anxiety disorder (Garcia-Garcia et al. 
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2008; Kinrys et al. 2009; Saeed et al. 2007). The usage 
of herbal and other natural remedies for the management 
and treatment of psychological conditions is timely due 
to the rising cost of prescription medications and their 
potential unwanted side effects to the patients.
 Herbs may improve cognitive function or reduce the 
risk of cognitive decline. For example, supplementation 
of American ginseng (Panax quinquefolius) was reported 
to increase the working memory performance up to 10% 
among young adults in Australia (Scholey et al. 2010). 
A modest improvement was found in the accuracy 
of working memory task after 14 day administration 
of Ginkgo biloba extract among middle-aged adults 
(Silberstein et al. 2011). In addition, supplementation of 
SuperUlam, a mixture of herbs containing about 14.5% 
Polygonum minus as well as other ingredients such as 
sireh extract, pegaga extract, turmeric extract, curry 
leaves extract and selasih extract have shown to improve 
cognitive function among healthy individual aged 35-65 
years old (Udani 2013). 
 P. minus is an aromatic plant originates from 
Southeast Asia, belonging to the family Polygonaceae 
and locally known as kesum. It has been used as a 
traditional remedy and for cooking purpose to provide 
flavour and fragrance. Previous study has reported that 
P. minus extract showed the highest antioxidant activity 
as compared to other popular herbs such as ‘pegaga’ 
and curry leaves (Huda-Faujan et al. 2009). P. minus 
is usually consumed as salad or ‘ulam’ (a Malaysian 
practice of complementing raw plants with rice dishes) 
(Al-Qari 2006; Cheah et al. 2008; Joseph et al. 2005; 
Sumazian et al. 2010; Tanaka 1976). Traditional usage 
of P. minus leaves decoctions includes treatment for 
dandruff, diarrhoea and indigestion (Herbal Medicine 
Research Centre 2002; Norliza et al. 2013). Nutrients 
found in P. minus include carotenes, retinol equivalents 
and L-ascorbic acid, α-tocopherol (vitamin E), calcium, 
phosphorus, iron, sodium, potassium, magnesium, copper 
and zinc (Ching & Mohamed 2001). It has been proven 
to be a potent natural source of antioxidant due to high 
antioxidant activity among other selected Malaysian 
plants (Azlim Almey et al. 2010; Qader et al. 2011). There 
were numerous compounds previously isolated from P. 
minus leaves including flavonoids namely myricetin, 
quercetin, isorhamnetin, catechin and rutin (Narasimhulu 
& Mohamed 2014; Qader et al. 2012). 
 Until recently, reports on the effect of P. minus on 
mood and quality of life are still limited. There is a need 
to explore the potential effect of P. minus on cognition and 
mood status since we have previously shown that 6 weeks 
supplementation of P. minus had improved short term 
memory and attention among subjects with poor mood 
and improved IQ among those with good mood (Suzana 
et al. 2015). Therefore, this study aimed to evaluate the 
benefits of P. minus supplementation towards mood and 
cognitive function among middle aged women.
MATERIALS AND METHODS
STUDY DESIGN
This study was a randomised, double-blind, placebo-
controlled trial assessing the effect of P. minus extract 
(LineMinusTM) on cognition and mood status among 
middle aged women in Klang Valley, Malaysia. Subjects 
were randomised into two groups, namely placebo or P. 
minus. Randomisation was conducted using random sample 
cases decided by statistical computer programme, Statistical 
package for Social Sciences version (SPSS). Blinding 
procedure is ensured by labelling the P. minus and placebo 
capsules as either A or B Only so that the manufacturer knew 
the coding for both A and B labelled capsules. 
DATA COLLECTION
A total of 63 subjects were recruited from the screening 
process which involved self-administered questionnaires, 
anthropometric and blood pressure measurement and a 
collection of 20 mL fasting venous blood after 8 to 10 h 
fasting for the analysis of HbA1C, serum lipid, renal profile 
and liver function. The inclusion criteria include women 
aged 35 to 55 years with body mass index (BMI) of less 
than 40.0 kg/m2. The exclusion criteria included individuals 
with or had a history of substance or alcohol abuse, history 
of major depression (marked as depressed mood most 
of the day) and bipolar disorder, had medical conditions 
problems (e.g. uncontrolled diabetes and kidney problem), 
pregnancy or lactation. A total of 35 subjects participated 
in the study and were randomly assigned into either 
placebo or intervention group. This study has obtained 
approval from the Medical Research Ethics Committee of 
the Universiti Kebangsaan Malaysia (NN-2014-060) and 
subjects have given their informed consent in accordance 
with the principles in the declaration of Helsinki (World 
Medical Association declaration of Helsinki, 2000) and 
Good Clinical Practice Guidelines.
INTERVENTION
This study was performed over a 6 week intervention 
period which includes three visits within the study 
period. Data collection was conducted from October until 
December 2014 at a few schools and a government office 
in Klang Valley in Malaysia. Each subject was randomly 
chosen where 17 subjects were selected from schools and 
the other 18 subjects were from government office. These 
subjects were evaluated for outcome measures including a 
cognitive function test battery, mood test and quality of life 
at three time points (baseline, week 3 and week 6). Blood 
profiles including HbA1C, serum lipid, renal profile, liver 
function and blood pressure were analyzed at baseline and 
week 6 to measure the effect of P. minus supplementation 
on health status. Subjects were advised to restrict their 
intake of caffeinated drinks no more than two cups daily on 
the testing days and to abstain the intake of any vitamins, 
other herbal supplements during the study period. 
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 The subjects were provided with two bottles of 
supplement each containing 60 capsules throughout the 
intervention period. The treatment group received capsules 
containing P. minus extract whilst the controlled group 
received placebo capsules containing 100 mg maltodextrin. 
The placebo used was a sensory-identical capsule. Both 
groups were required to take two capsules once daily 
preferably in the morning. Subjects were required to record 
the time of consumption each day and noted down the 
reason for not taking the products if any in a diary provided 
to them for compliance checking. Both diary and capsules 
were brought back to the study site during scheduled visits 
and daily reminder was performed through phone call or 
short message service (SMS). Compliance of the subjects 
was monitored regularly whereby about 98.3% of the given 
capsules were consumed by the subjects. 
STUDY PRODUCT
The supplements capsule, LineMinusTM was a 
standardized water extract of P. minus leaves with a ratio 
of water to dried leaves of P. minus (1:20) (George et al. 
2014; Ming et al. 2013). A finished product contained 250 
mg of P. minus extract for each besides containing about 
0.4% and 0.1% Quercetin-3-glucuronide and Quercitrin, 
respectively. Table 1 shows the constituents of both 
placebo and P. minus. This product has passed microbial 
limit test with absence of several microbes in the products 
and were reported to be free from Salmonella, Escherichia 
coli and Staphylococcus aureus. The level of several heavy 
metals such as arsenic, cadmium, lead and mercury were 
analyzed and passed within the regulated limits. Reference 
from previous study that stated no-observed-adverse-effect 
level (NOAEL) of P. minus extract in Wistar rats following 
oral administration for 28 days at more than 1000 mg/kg 
body weight was used to determine the dosage of two 
capsules (i.e. 500 mg/d) (Ming et al. 2013). According 
to the manufacturers’ guidelines, this supplement only 
can be used traditionally for general health and not 
recommended for pregnancy and lactation women due to 
lack of sufficient data. 
OUTCOME MEASURES
Cognitive function, mood and quality of life are the primary 
outcome of this study. These variables were measured 
through Digit Span (Groth-Marnat 2000), Rey Auditory 
verbal learning test (RAVLT) (Rey 1964), comprehensive 
trail making test (CTMT) (Reynolds 2002), Wechsler 
abbreviated scale of intelligence (WASI) (Wechsler 1999) 
and CNS vital sign (CNSVS) (Gualtieri & Johnson 2006), 
profile of mood states (POMS) (McNair et al. 1971) and 36-
Item short form health survey (SF-36) (Brazier et al. 1992). 
Anthropometry and body composition measurements were 
the secondary outcomes and measured at baseline, week 3 
and week 6. The anthropometric parameters were measured 
with minimal clothing using TANITA digital lithium scale 
HD319 to the nearest 0.1 kg, (TANITA Corporation, Japan) 
for body weight and Leicester Portable Height Measure 
(SECA, German) for height. A total of 20 mL of fasting 
blood samples were taken for analysis of fasting serum 
lipid, liver and renal function test (triglycerides, total 
cholesterol, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol) and HbA1C were measured 
at baseline and 6 weeks. Blood pressure measurement 
was performed using an automated monitor (Omron HEM 
7321-E, Netherlands). At each visit, subjects were asked 
by research assistants for any symptoms or side effects 
that they experienced. 
TABLE 1. Energy, nutrient, and bioactive profile of P. minus preparation, LineMinusTM and placebo capsules
Constituents (per 100 g) Placebo P. minus preparation, LineMinusTM
Energy1
  (kJ)
  (kcal)
Macronutrients1
  Fat (g)
  Carbohydrate (g)
  Protein (g)
Micronutrients 2,3
  Calcium (mg)
  Iron (mg)
  Vitamin A (µg)
  L-ascorbic acid (mg)
  α-tocopherol (mg)
Bioactive content (%)3
 Quercetin-3-glucuronide
 Quercitrin
386
1621
0
94
2.6
6.3
0.4
0
10.6
0
-
-
305
1281
0
67.6
8.6
38.5
1.4
0
27.0
0
0.4
0.1
1 Determined by Method of Analysis for Nutritional Labeling, AOAC 1993
2 Determined by U.S Environmental Protection Agency Method (EPA) revision 2, 1995
3 Determined by High Performance Liquid Chromatography (HPLC)
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STATISTICAL ANALYSIS
Data was analysed using Statistical package for Social 
Sciences version (SPSS) 20 (v 20.0; IBM Corporation, 
Armonk, NY, USA). Data normality was determined from 
the Shapiro-Wilk test. The results were stated as either 
mean ± standard deviation (SD), frequency or percentage 
or with 95% confidence interval. The variations between 
the treatment and the placebo groups were analysed 
using independent student t-test and chi squared test. 
Paired sample t-tests were used for within subjects means 
comparisons between control and intervention groups 
at baseline, Week 3 and Week 6. All tests were 2-tailed 
with p values less than 0.05 were considered statistically 
significant. 
RESULTS
A total of 63 subjects were screened, with 43 were eligible 
and consented to participate. However, 35 were included 
in the final analysis, as four had health problems that 
interfered with the protocol of the study and one subject 
was lost to follow up giving with 87.5% response rate 
(Figure 1). After randomisation, a total of 18 subjects in 
placebo group and 17 subjects in the intervention group 
were allocated. Demographic profiles of the subjects 
according to the supplementation group are presented 
in Table 2. Mean age of the subjects were 45.6±6.1 and 
44.7±4.6 years, for placebo and P. minus, respectively. All 
of the subjects were Malays and both groups showed no 
significant difference with respect to socio-demographic 
profile. Anthropometric status which includes weight, 
height and BMI showed no significant difference between 
groups. 
 Table 3 shows the result of blood biomarkers 
changes from baseline after 6 weeks of supplementation 
in both group placebo and P. minus. Both placebo and P. 
minus group showed no significant difference in blood 
biomarkers at baseline. In the intervention group, there 
was a significant decrease (p<0.05) of mean in uric acid, 
estimated glomerular filtration rate (eGFR), ratio total 
cholesterol to HDL and HbA1C from baseline (303.2±71.3 
umol/L, 95.1±19.9 mL/min/1.73m2, 3.3±1.0 mmol/L and 
5.7±0.4) to week 6 (271.2±57.2 umol/L, 86.0±18.2 mL/
min/1.73m2, 3.2±0.7 mmol/L and 5.4±0.3). The mean of 
q
q
q
q
q
q
q
q
Enrollment
Allocation
Follow-Up
Analysis
• Analysed (n= 18)
• Excluded from analysis (Chinese subjects) (n= 2 )
• Completed intervention (n=20)
• Lost to follow-up (could not be contacted) (n= 1)
• Discontinued intervention (pregnant) (n=1)
Group A
Placebo group
Allocated to intervention (n= 22)
Group B
P. minus group
Allocated to intervention (n= 21)
Randomised (n= 43)
Assessed for eligibility (n= 63)
Excluded (n= 20)
• Not meeting inclusion criteria (n=12)
• Declined to participate (n= 8)
• Completed intervention (n=18)
• Lost to follow-up (could not be contacted) (n= 1)
• Discontinued intervention (kidney problems) (n= 2)
• Analysed (n= 17)
• Excluded from analysis (male subjects)  (n= 1 )
FIGURE 1. Flow diagram of study
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TABLE 2. Baseline characteristics of participants by intervention and placebo group
Baseline characteristics Placebo(n= 18 )
P. minus
(n= 17)  P value
Mean age (year)1
Marital status2
  Married 
  Single 
Level of education2 
  Secondary school
  Certificate/Diploma
  Degree 
Occupation2 
  Teacher 
 Non-teacher
 Mean household income (RM)1
Anthropometric status1
  Weight (kg)
  Height (cm)
  BMI (kg/m2)
45.6±6.1
20 (100.0%)
0 (0.0%)
8 (44.4%)
2 (11.1%)
8 (44.4%)
8 (44.4%)
10 (55.6%)
7591.1±3904.2
67.3±9.7
155.7±5.0
27.7±3.9
44.7±4.6
17 (94.1%)
1 (5.9%)
4 (23.5%)
4 (23.5%)
9 (52.9%)
9 (52.9%)
8 (47.1%)
8250.6±5125.1
66.9±11.7
154.3±5.5
28.2±5.0
0.6231
0.296 2
0.362 2
0.615 2
0.6701
0.9291
0.4121
0.7341
1Continuous data were presented as mean ± standard deviation, 2Categorical data were presented as number (%), RM: Ringgit Malaysia
TABLE 3. Data on blood biomarkers at baseline and 6 weeks of intervention in control and intervention group (mean ± SD)
Parameters
Placebo (n=18) P. minus (n=17)
Baseline
(mean ± SD)
Week 6
(mean ± SD)
Baseline
(mean ± SD)
Week 6
(mean ± SD)
Renal profil
 Sodium (mmol/L)
 Potassium (mmol/L
 Urea (mmol/L)
 Uric acid (umol/L)
 Creatinine (umol/L)
 eGFR (mL/min/1.73m2)
Liver function test
 Total protein (g/L)
 Albumin (g/L)
 Globulin (g/L)
 Bilirubin (umol/L)
 Alkaline phosphatase (U/L) 
 GGT (U/L)
 Aspartate transferase (AST) (U/L)
 Alanine transaminase (ALT) (U/L)
Lipid profile
 Total cholestrol (mmol/L)
 Triglycerides(mmol/L)
 HDL (mmol/L)
 LDL (mmol/L)
 Total cholestrol/HDL (mmol/L)
 HbA1C (%)
140.7±1.6
4.2±0.2
3.7±1.1
302.4±65.4
59.8±7.6
96.1±15.5
78.1±3.4
44.8±2.1
33.2±3.7
10.8±5.9
73.9±20.2
27.0±21.1
22.6±7.1
21.9±11.9
71±18.0
5.4±0.9
0.9±0.4
1.5±0.3
3.5±0.9
3.7±1.1
5.9±0.8
142.7±1.9c
4.5±0.5a
3.7±0.9
290.7±69.5
65.1±8.8c
87.0±13.0c
76.9±3.0a
44.5±1.9
32.5±2.9
10.4±6.5
73.8±19.7
27.4±20.0
24.0±11.4
19.7±9.8
74±17.5
5.4±0.9
0.9±0.3
1.5±0.3
3.5±0.8
3.8±1.0
5.6±7.4b
140.8±2.1
4.3±0.4
3.7±0.8
303.2±71.3
61.3±9.1
95.1±19.9
79.4±3.3
44.9±2.9
34.6±3.5
10.6±4.9
72.6±14.7
28.5±12.9
21.2±6.7
19.9±14.5
66±16.8
5.3±1.2
0.9±0.2
1.7±0.4
3.2±1.0
3.3±1.0
5.7±0.4
141.5±2.6
4.4±4.2
3.5±1.0
271.2±57.2a
66.6±10.0c
86.0±18.2c
77.6±4.6
44.3±3.3
33.5±4.5
9.2±3.4
76.9±23.5
34.8±41.6
32.4±30.4
33.3±40.6
72±14.9
5.4±1.3
1.0±0.5
1.7±0.4
3.3±0.7
3.2±0.7a
5.4±0.3c
*p<0.05 mean difference between placebo and P. minus at baseline
**p<0.05 mean changes between placebo and P. minus from baseline and week 6
ap<0.05, bp<0.01, cp<0.001
HDL: High density lipoprotein, LDL: Low density lipoprotein, HBA1c: Glycated hemoglobin
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creatinine increased significantly (p<0.05) from baseline 
(61.3±9.1 umol/L) to week 6 (66.6±10.0 umol/L). In 
placebo group, mean of renal profile include sodium, 
potassium and creatinine had significantly increase from 
baseline (140.7±1.6, 4.2±0.2 and 59.8±7.6 umol/L) to week 
6 (142.7±1.9, 4.5±0.5 and 65.1±8.8 umol/L). Meanwhile 
decreasing in mean was noted in eGFR and HbA1c from 
baseline (96.1±15.5 mL/min/1.73 m2 and 5.9±0.8) to week 
6 (87.0±13.0 mL/min/1.73m2 and 5.6±7.4) in placebo 
group. However, no significant difference in mean changes 
between both groups after 6 weeks of intervention.
 There was no significant difference in psychosocial 
status for both groups at baseline except for depression, 
fatigue, confusion and total mood disturbance. A significant 
decrease of mean POMS (tension, depression, anger and 
TMD (Total Mood Disturbance)) were observed in the 
intervention group from baseline (10.9±4.5, 11.8±6.4, 
11.7±4.9 and 32.0±21.8) to week 6 (8.6±5.0, 8.1±8.2, 
8.7±6.1 and 21.1±25.1) with p value of 0.038, 0.019, 
0.011 and 0.010, respectively (Table 4). Mean changes 
in POMS (anger) was significantly difference in P. minus 
group compared to placebo from baseline to week 6. 
Furthermore, mean of quality of life (energy/fatigue, social 
functioning and general health) in the intervention group 
have significantly increased from baseline (62.4±15.9, 
79.4±19.7, 65.6±16.8) to week 6 (68.2±13.7, 91.9±8.8 
and 71.8±14.1) with p value of 0.022, 0.008 and 0.028, 
respectively. There were no significant difference in both 
parameters of mood and quality of life in placebo group.
 Improvement in the mean score of digit span, CTMT 
(Trail 1, Trail 2, Trail 5 and Composite Index), WASI (IQ 
performance and IQ full) and CNSVS (cognitive flexibility, 
psychomotor speed and executive function) from baseline 
to week 6 was found for both groups (Table 5). However, 
only CTMT (Trail 3) shows significantly difference in 
mean changes between treatment and placebo group at 
week 3 and baseline. In addition, CTMT (Trail 5) shows 
a significant difference in mean changes between both 
groups at baseline and week 6. Mean score for digit span 
improved from baseline to week 6 (p=0.030) in P. minus 
group and in placebo group (p=0.005). Both groups showed 
an increment in the mean score for CTMT composite index 
for baseline and week 6. In addition, P. minus exert highly 
significant difference (p=0.001) as compared to the placebo 
group (p<0.05) from baseline to week 6 in the Full Scale IQ 
of WASI. Similar trend was observed for executive function 
in CNSVS which shown higher significant level in P. minus 
group as compared to placebo group. Besides, significant 
improvement in cognitive flexibility domain in CNSVS 
was seen from week 3 for P. minus group, but was only 
TABLE 4. Data on psychosocial status at baseline, 3 weeks and 6 weeks of intervention in control (mean ± SD) 
and intervention group (mean ± SD)
Parameters
Baseline (mean ± SD) Week 3 (mean ± SD) Week 6 (mean ± SD)
Placebo
(n=18)
P. minus
(n=17)
Placebo
(n=18)
P. minus
(n=17)
Placebo
(n=18)
P. minus
(n=17)
POMS
  Tension 
  Depression 
  Anger 
  Vigour 
  Fatigue 
  Confusion 
  Total mood
  disturbance 
SF-36
  Physical 
  Functioning
  Role limitation due 
to physical health
  Role limitation due to 
emotional problems
  Energy/fatigue
  Emotional wellbeing
  Social functioning
  Bodily pain
  General health
8.3±3.8
5.3±4.7
8.3±5.4
19.6±7.1
6.2±3.4
5.6±2.3
14.2±16.2
90.0±11.4 
75.0±35.4
88.9±28.0
67.2±14.8
78.0±10.5
84.0±19.6
79.0±18.9
70.6±18.0
10.9±4.5
11.8±6.4*
11.7±4.9
19.2±5.2
9.1±4.2*
7.6±2.6*
32.0±21.8*
82.6±17.6 
79.4±29.6
78.4±37.2
62.4±15.9
73.2±13.7
79.4±19.7
69.9±17.8
65.6±16.8
9.7±6.0
9.2±10.4
9.3±7.7
18.8±5.1
7.7±5.6
7.3±4.0
24.8±29.7
89.2±11.9 
73.6±34.8
98.1±7.7
72.8±14.6
82.4±9.1
88.9±15.4
83.6±14.0
74.4±17.5
8.6±5.6
7.9±9.4
9.1±6.5
17.7±5.3
7.4±5.3
6.7±3.2
21.2±30.9
86.8±12.6 
75.0±35.4
82.4±31.4
69.4±13.7a
77.9±13.4
90.4±10.4a
78.4±15.1
72.1±14.9
8.4±5.4
7.2±10.5
8.9±5.4
19.7±5.7
6.4±5.6
6.7±4.0
18.1±29.4
91.7±9.7 
72.2±39.2
90.7±27.5
70.3±19.0
77.3±17.5
85.4±15.0
83.2±19.8
71.7±20.3
8.6±5.0c
8.1±8.2c
8.7±6.1***c
18.6±4.6
7.3±4.6
6.6±3.2
21.1±25.1c
86.9±13.3 
88.2±33.2
92.2±22.1
68.2±13.7c
76.0±12.6
91.9±8.8c
73.8±10.1
71.8±14.1c
*p<0.05 mean difference between placebo and P. minus at baseline
**p<0.05 mean changes between placebo and P. minus from baseline and week 3, ***p<0.05 mean changes between placebo and P. minus from baseline and week 6 
a p<0.05 at baseline and week 3, bp<0.05 at Week 3 and Week 6,cp<0.05 at baseline and Week 6
POMS: Profile of Mood States, SF-36: 36-Item Short form Health Survey
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seen at week 6 for placebo group. No adverse effects were 
reported by the subjects from both groups throughout the 
study period.
DISCUSSION
To date, most of previous studies have focused on 
assessing the efficacy of P. minus on animal (George et 
al. 2014; Ming et al. 2013; Norliza et al. 2013). Hence, 
there are a limited number of studies reporting on the 
efficacy of P. minus extract supplementation on cognitive 
function, mood status and quality of life in human. In this 
present study, 6 week supplementation of P. minus extract 
among healthy women aged 35 to 55 years was found to 
improve some domains in mood state and quality of life. 
Significant improvements were noted in POMS for tension, 
depression, anger and total mood disturbance and SF-36 
domain including energy/fatigue, social functioning and 
general health in P. minus group. With respect to quality 
of life assessed by SF-36, the significant improvement was 
seen from week 3 onward for energy/fatigue and social 
functioning domain. Whereas, there was no improvement 
seen in the placebo group for mood and quality of life until 
week 6 of supplementation. 
 Several studies have reported that leaves of P. minus 
are high in phytochemicals particularly flavonoid which 
associated with their antioxidant activity (Maizura et al. 
2011; Urones et al. 1990). Flavonoid possessed the ability to 
delay or prevent degenerative diseases caused by oxidative 
damage, thus facilitate in the reduction of oxidative stress 
and lipid peroxidation in neuronal membranes (Spencer 
2009). To exert the effect on cognition or mood, flavonoids 
must arrive at the central nervous system (CNS) through 
the blood brain barrier (Jäger & Saaby 2011). Studies 
have shown that quercetin-3-glucuronide can be absorbed 
through the small intestine and reach the central nervous 
system (CNS) (Lee et al. 2001). In a cell culture study, 
quercetin extracted from onion has been reported to 
permeate across the blood brain barrier and has the ability 
to impede the neuron cell death by hydrogen peroxide (Dan 
et al. 2011). In an animal study, oral administration of 
quercetin has shown to reduce the increment of oxidative 
TABLE 5. Data on cognition at baseline, 3 weeks and 6 weeks of intervention in control 
(mean ± SD) and intervention group (mean ± SD)
Parameters
Baseline (mean ± SD) Week 3 (mean ± SD) Week 6 (mean ± SD)
Placebo 
(n=18)
P. minus 
(n=17)
Placebo 
(n=18)
P. minus 
(n=17)
Placebo 
(n=18)
P. minus 
(n=17)
Digit span
RAVLT
 Learning 
 Recall 
CTMT
  Trail 1
  Trail 2
  Trail 3
  Trail 4
  Trail 5
  Composite index
WASI
  IQ verbal
 IQ performance
  IQ full
CNS Vital Sign
  Visual memory
  Psychomotor speed
  Reaction time
  Cognitive flexibility
  Processing speed
  Executive function
  Motor speed
8.2±1.8
48.7±10.4
50.1±9.9
38.8±9.5
44.8±8.7
41.6±10.2
41.2±9.5
42.0±8.2
40.6±8.0
109.7±11.6
111.3±10.1
111.6±9.3
83.7±18.6
89.1±22.0
92.3±16.3
97.2±14.9
101.5±15.1
100.1±14.2
85.2±25.1
8.8±2.5
51.8±9.3
51.4±7.4
40.2±7.0
43.6±7.9
42.6±9.5
39.1±6.0
44.1±5.6
40.8±6.6
108.5±10.3
107.1±11.8
108.7±10.0
87.8±12.7
99.3±13.7
84.1±17.8
94.1±11.9
102.6±14.4
95.2±11.4
97.0±14.3
10.1±3.3a
50.2±12.1
50.4±10.1
48.6±7.0 a*
51.7±11.3a
46.6±10.0a
43.4±11.0
47.1±10.2 a 
46.7±8.7a
108.5±6.3
116.4±10.5a
114.2±8.2
80.2±14.5
90.3±16.6
95.3±15.3
104.1±15.9
106.4±15.5a
105.3±13.3
83.3±18.3
9.5±1.5
50.4±6.1
49.4±9.6
47.6±6.3 a*
42.9±5.8
47.2±10.2**a
42.9±7.8
44.8±7.6
44.2±6.4a 
107.2±7.0
114.9±6.9a
112.2±6.6
88.3±13.2
98.2±14.4
90.9±14.3a
101.9±12.7a
107.0±17.2
102.4±12.9a
93.4±15.9
9.8±2.5c
49.1±10.7
49.0±10.3
52.0±10.0 b, c*
52.1±11.8 b, c
49.5±10.4c
44.1±8.7
50.9±8.0 b, c*
49.2±9.1b, c*
109.1±5.8
117.8±6.0b, c
114.5±5.0c
83.0±16.3
95.2±16.6
97.6±11.9
108.0±11.3c
109.6±24.5c
108.2±11.7c
87.5±13.2
9.8±2.0c
51.2±7.9
51.0±7.5
49.8±8.1c*
49.6±11.5c
46.1±7.3
45.5±7.9c
48.3±7.5***c
47.2±7.0c*
108.8±5.7
119.2±8.4***c*
115.6±6.0c
85.8±16.3
103.2±16.6b
90.6±11.9
107.0±11.3c*
114.8±24.5b, c
107.0±11.7c*
94.5±13.2
*p<0.05 mean difference between placebo and P. minus at baseline
**p<0.05 mean changes between placebo and P. minus from baseline and week 3, ***p<0.05 mean changes between placebo and P. minus from baseline and week 6
a p<0.05 at baseline and Week 3,a*p<0.01 at baseline and Week 3,bp<0.05 at Week 3 and Week 6,cp<0.05 at baseline and Week 6,c*p<0.01 at baseline and Week 6
RAVLT: Rey Auditory Verbal Learning Test, CTMT: Comprehensive trail making test, WASI: Wechsler Abbreviated Scale of Intelligence, CNS Vital Sign: Central Nervous 
System Vital Sign
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stress in the brain thus proved the ability of this compound 
to permeate to the brain (Ishisaka et al. 2011). Although in 
the present study we have not measure the bioavailability of 
quercetin from P. minus, previous supplementation studies 
using quercetin have reported the increase in plasma level 
of quercetin after two week up to 12 weeks administration 
(Egert et al. 2008; Jin et al. 2010).
 Quercetin and quercetin-3-glucuronide were reported 
to have an impact on gamma-aminobutyric acid (GABA) 
receptors producing sedation, anxiolytic or anticonvulsive 
effects (Jäger & Saaby 2011). In addition, structural 
formula of P. minus extract which consist of two flavonoids 
namely quercetin-3-glucoronide and quercitrin has been 
reported to possess anti-depression property (Pathak 
et al. 2013). Thus, these components found in P. minus 
extract might explain its ability in improving mood state 
particularly in tension, depression, anger and total mood 
disturbance and domain in SF-36 (energy/fatigue, social 
functioning and general health). Similarly, Udani (2013) 
has observed a significant improvement in tension, 
depression and anger of POMS after the supplementation of 
SuperUlam, a mixture of natural herbs including P. minus. 
The synergistic effect mixture of vitamins and minerals in 
P. minus capsule also might potentially affect the mood 
parameters. Previous study among elderly has reported 
that supplementation of multivitamin formulation consist 
of vitamins, minerals, antioxidants and herbal extracts has 
improved alertness and reducing negative mood symptom 
in the intervention group (Harris et al. 2011). Study by 
Tildesley et al. (2005) has suggested an improvement in 
mood after acute administration of Salvia lavandulaefolia 
in the form of capsule. Supplementation of Nigella sativa 
L. or also known as black cumin for four weeks has shown 
to improve mood and decrease anxiety through their potent 
antioxidant and anticholinesterase activities of the herbs 
(Sayeed et al. 2014). On the contrary, Panax ginseng has 
shown no effect on total mood disturbance after 8 weeks 
supplementation with different dosages (Cardinal & Engels 
2001). The effect of herbal supplementation on mood 
can vary according to dosage, duration and the forms of 
supplementation given to the subjects.
 In the present study, both P. minus and control group 
have shown an improvement in cognitive test administered. 
One of the possible explanations is due to practice 
effect. This term has been defined as the improvements 
in cognitive performance caused by practicing a task 
or repetition of the cognitive battery (Heiman 2002). 
Participants were required to repeat the same version 
of cognitive tests during baseline, week 3 and week 
6, thus, this might exposed them to practice effect and 
led to an improvement in cognitive performance. In the 
present study, only computerized CNSVS had different 
test versions. Study by Collie et al. (2003) has reported a 
significant improvement due to practice effect after first 
and second administration of cognitive test battery to the 
subjects. However, the following administration did not 
show any improvement in the test performance. Although 
practice effect has been linked as a source of error, earlier 
study has suggested that it can be a beneficial tool to 
monitor cognitive status specifically among patients with 
neurodegenerative disorders at earlier stage (Duff et al. 
2007). 
 There are some strengths in this study that enhance 
confident in the results obtained, including the use of 
randomised, double-blind, placebo controlled methods, 
a full 6 weeks supplementation, blood monitoring at 
baseline and week 6 of the study and multiple assessments 
of cognition test. However, this study is limited by a short 
duration of supplementation. In addition, only one male 
subject has successfully completed the study and the 
data was excluded from the analysis, thus no comparison 
between genders can be made. This research will serve as a 
base for future studies to investigate the benefits of P. minus 
supplementation on cognitive and mood in a wide range 
of population which include different genders and races. 
Moreover, it would be interesting to assess the mechanism 
of action of P. minus specifically on mood.
CONCLUSION
In conclusion, this study suggested that 6 weeks 
supplementation of P. minus (LineMinus™) had 
significantly improved mood specifically in tension, 
depression, anger and total mood disturbance. Similarly, 
the same trend was found for quality of life components 
including energy/fatigue, social functioning and general 
health. On the other hand, improvements in cognitive 
functions were observed in both intervention and control 
group. Further investigations in determining the effect 
of P. minus at cellular and molecular level are strongly 
recommended.
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